Public

Corcept Therapeutics (CORT) agreed to settle $14 million with investors to end a securities class action lawsuit over concealing that it improperly paid doctors to promote its drug Korlym and inflated its revenue and sales using illicit sales practices through a related party.

Corcept Therapeutics Incorporated

All persons who purchased or otherwise acquired common stock or options to purchase common stock of Corcept Therapeutics Incorporated during the period between August 2, 2017 to January 31, 2019, inclusive.

Do I have to sell securities to be eligible?

No, if you have purchased securities within the class period, you are eligible to participate.

You can participate in the settlement and retain (or sell) your securities.

The final payout amount depends on your specific trades and the number of investors participating in the settlement.

If 100% of investors file their claims - the average payout will be $0.06 per share. Although typically only 25% of investors file claims, in this case, the average recovery will be $0.24 per share.

The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.

11thestate is an investor recovery company, we help investors to track and collect securities class action settlements. We will:

Audit the claim and make sure you get the maximum possible payout

File a claim with the settlement administration

Correspond with the settlement administration to resolve emerging issues

Deliver payout directly to your brokerage account

There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.

Accepting Late Claims

Misleading Statements

Financial Misrepresentation

Failure to Disclose

Omissions

Directors

Management

Corcept Therapeutics (CORT) $14M Securities Settlement

corcept-securities-settlement

Stocks

Long

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics (CORT) $14M Securities Settlement

Corcept Therapeutics (CORT) agreed to settle $14 million with investors to end a securities class action lawsuit over concealing that it improperly paid doctors to promote its drug Korlym and inflated its revenue and sales using illicit sales practices through a related party.

Frequently Asked Questions